Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has results × dostarlimab × Clear all

Phase

Phase 2 8 Phase 1 5 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Carboplatin 150 Cisplatin 147 Paclitaxel 145 Docetaxel 113 Cyclophosphamide 112 Dexamethasone 98 Doxorubicin 94 Gemcitabine 87 Bevacizumab 87 pembrolizumab 86 Prednisone 79 Rituximab 77 Fluorouracil 67 Pemetrexed 65 Vincristine 64 Radiotherapy 63 Etoposide 62 Nivolumab 57 Capecitabine 54 Leucovorin 53 Trastuzumab 52 Cytarabine 48 Methotrexate 42 Oxaliplatin 38 atezolizumab 36 Filgrastim 36 Lenalidomide 35 Irinotecan 33 Bortezomib 33 Sorafenib 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡